medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2004, Number 3

<< Back Next >>

Alerg Asma Inmunol Pediatr 2004; 13 (3)

Immune response in Kawasaki disease

Aviña FJA, López BR, Toro CJL

Language: Spanish
References: 23
Page: 104-108
PDF size: 129.43 Kb.


ABSTRACT

The Kawasaki disease is a systemic vasculitide of probable infectious etiology, that it includes an immune response in cascade with clinical disease characterized by high fever persisting at least five days and the presence of at least four of the following principal features: conjunctival injection without exudates, cervical lymphadenopathy no supurative, changes in lips and oral cavity, erythema and cracking of lips, strawberry tongue, diffuse injection of oral an pharyngeal mucosae; polymorphous exanthem; changes in extremities like acute erythema and edema of hands and feet with late desquamation of fingertips. This is a review of the immunological bases that summarizes the recent results of medical investigations reported in world-wide literature. The objective is to provide an up to date of these new knowledges, to allow a better understanding of the immune response of the Kawasaki disease.


REFERENCES

  1. Brogan PA, Bose A, Burgner D, Shingadia D, Tulloh R, Michie C, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment and proposal for future research. Arch Dis Child 2002; 86: 286-90.

  2. Meissner HC, Leung DY. Kawasaki syndrome: where are the answers? Pediatrics 2003; 112: 672-5.

  3. Meissner HC, Leung DY. Superantigens, conventional antigens and the etiology of Kawasaki syndrome. Pediatr Infect Dis J 2000; 19: 91-4.

  4. Suzuki H, Noda E, Miyawaki M, Takeuchi T, Uemura S, Koike M. Serum levels of neutrophil activation cytokines in Kawasaki disease. Pediatr Int 2001; 43: 115-9.

  5. Sohn MH, Noh SY, Chang W, Shin KM, Kim DS. Circulating interleukin 17 is increased in the acute stage of Kawasaki disease. Scand J Rheumatol. 2003; 32: 364-6.

  6. Chua PK, Malish ME, Yu Q, Yanagihara R, Yamamoto KS, Nerurkar VR. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Clin Diagn Lab Immunol 2003; 10: 308-14.

  7. Jang GC, Kim HY, Ahn SY, Kim DS. Raised serum interleukin 15 levels in Kawasaki disease. Ann Rheum Dis 2003; 62: 264-6.

  8. Shikishima Y, Saeki T, Matsuura N. Chemokines in Kawasaki disease: measurement of CCL2, CCL22 and CXCL10. Asian Pac J Allergy Immunol 2003; 21: 139-43.

  9. Terai M, Yasukawa K, Honda T, Jibiki T, Hirano K, Sato J, Ishiwada N, Seguchi M, Ueda S, Kohno Y. Peripheral blood eosinophilia and eosinophil accumulation in coronary microvessels in acute Kawasaki disease. Pediatr Infect Dis J 2002; 21: 777-81.

  10. Suzuki H, Muragaki Y, Uemura S, Takeuchi T, Minami T, Shibura S, Ohshima A, Yoshikawa N. Detection of auto-antibodies against a 70 kDa protein derived from vascular smooth muscle cells in patients with Kawasaki disease. Eur J Pediatr 2002; 161: 324-9.

  11. Biezeveld MH, Kuipers IM, Geissler J, Lam J, Ottenkamp JJ, Hack CE, Kuijpers TW. Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. Lancet 2003; 361: 1268-70.

  12. Furui J, Ishii M, Ikeda H, Muta H, Egami K, Sugahara Y, Himeno W, Akagi T, Kato H, Matsuishi T. Soluble forms of the selectin family in children with Kawasaki disease: prediction for coronary artery lesions. Acta Paediatr 2002; 91: 1183-8.

  13. Takeshita S, Kawase H, Shimizu T, Yoshida M, Sekine I. Increased production of serum IgA-class antibody to lipid A in Kawasaki disease. Pediatr Int 2002; 44: 5-11.

  14. Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001; 166: 1334-43.

  15. Gupta J, Johann-Liang R, Bussel JB, Gersony WM, Lehman TJ. Elevated IgA and IgM anticardiolipin antibodies in acute Kawasaki disease. Cardiology 2002; 97: 180-2.

  16. Khajoee V, Kariyazono H, Ohno T, Ihara K, Mizuno Y, Kusuhara K, Hara T. Inducible and endothelial constitutive nitric oxide synthase gene polymorphisms in Kawasaki disease. Pediatr Int 2003; 45: 130-4.

  17. Yu X, Hirono KI, Ichida F, Uese KI, Rui C, Watanabe S, Watanabe K, Hashimoto I, Kumada T, Okada E, Terai M, Suzuki A, Miyawaki T. Enhanced iNOS expression in leukocytes and circulating endothelial cells is associated with the progression of coronary artery lesions in acute Kawasaki disease. Pediatr Res 2004; 55: 688-94.

  18. Samada K, Igarashi H, Shiraishi H, Hatake K, Momoi MY. Increased serum granulocyte colony-stimulating factor correlates with coronary artery dilatation in Kawasaki disease. Eur J Pediatr 2002; 161: 538-41.

  19. Wang CL, Wu YT, Liu CA, Lin MW, Lee CJ, Huang LT, Yang KD. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics 2003; 111: 140-7.

  20. Chua PK, Yanagihara R, Melish ME, Nerurkar VR. Modulation of adhesion molecules and monocyte chemoattractant protein by tumor necrosis factor-alpha and salicylic acid in primary human coronary artery endothelial cells. Cell Mol Biol 2003; 49: 1157-66.

  21. Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol 2001; 21: 193-9.

  22. Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004; 144: 496-9.

  23. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004; 31: 808-10.




2020     |     www.medigraphic.com